Several studies have shown that detection of PD-L1 protein on tumour cells before treatment correlates with a positive response to checkpoint inhibitors. However, some patients who seem to be PD ...

Michael Nash from the Department of Chemistry at the University of Basel, the study focuses on PD-L1, a protein that tumors use to hide from the immune system. In many cancers, PD-L1 acts as a ...

Their work, published in the Journal of the American Chemical Society, focuses on understanding how therapeutic proteins ...

How do atezolizumab and bevacizumab work? Atezolizumab is a type of immunotherapy called a monoclonal antibody. It works by binding to PD-L1 proteins on the surface of cancer cells. This stops cancer ...

Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.